Frontlight ResearchEarly access
Active, not recruitingPhase 3
Post-exposure Influenza Prophylaxis in a Hospital Setting
Key facts
- Who runs it
- University Medical Centre Ljubljana
- Where
- Slovenia1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Active, not recruiting
- Phase
- Phase 3
- People taking part
- 200 people, planned
- Started
- 1 Dec 2025
- Expected to end
- 31 Mar 2028
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Oseltamivir
- Record updated
- 30 April 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- 18 years or older
- exposure to influenza during hospitalization
- risk factors for influenza complications
- consent for participation obtained
Who cannot take part
- hematological malignancy
- younger than 18 years
- hospitalized in intensive care unit
- refusal to participate
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The purpose of this study is to compare the efficacy of 5-day versus 10-day oseltamivir prophylactic treatment in patients who had been exposed to influenza in a hospital setting.
The 2 groups in the trial
- oseltamivir 5 daysExisting treatment, for comparison
post-exposure influenza prophylaxis with oseltamivir for 5 days
Treatment: Oseltamivir
- oseltamivir 10 daysExisting treatment, for comparison
post-exposure influenza prophylaxis with oseltamivir for 10 days
Treatment: Oseltamivir
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Post-Exposure Influenza Chemoprophylaxis With Oseltamivir for Five Days vs Ten Days in Acute-Care Hospital: a Non-Inferiority Randomized Open-Label Study
- Record updated
- 30 April 2026